Analysts Set Average Price Target of $5.88 for KORU Medical Systems

KORU Medical Systems, Inc. (NASDAQ:KRMD) has received a consensus recommendation of “Moderate Buy” from six brokerages currently covering the company, according to MarketBeat Ratings. This analysis reflects a diverse range of opinions, with one analyst issuing a sell rating, one a hold rating, three assigning a buy rating, and one giving a strong buy rating.

The average target price set by these brokerages for KORU Medical Systems over the next twelve months is approximately $6.1250. Recent evaluations have offered insights into the stock’s potential, with various firms adjusting their ratings and price targets.

Recent Analyst Ratings and Price Targets

On January 12, 2024, Wall Street Zen upgraded KORU Medical Systems from a “buy” rating to a “strong buy.” Earlier, on December 22, 2023, Lake Street Capital raised their price target on the stock from $6.00 to $8.00, maintaining a “buy” rating. In another report dated December 17, 2023, Canaccord Genuity Group increased their target price from $5.00 to $6.00, also assigning a “buy” rating.

Conversely, Weiss Ratings reiterated a “sell (d-)” rating on October 8, 2023, indicating a more cautious outlook. These varying assessments highlight the mixed sentiments among analysts regarding the company’s future performance.

KORU Medical Systems Market Performance

As of the latest trading session, shares of KORU Medical Systems opened at $5.51, reflecting a decline of 2.8%. The company boasts a market capitalization of approximately $255.24 million, with a price-to-earnings (PE) ratio of -68.88 and a beta of 0.51. KORU Medical Systems has shown resilience in the market, with a current ratio of 2.48, a quick ratio of 1.92, and a minimal debt-to-equity ratio of 0.01.

The stock has experienced fluctuations over the past year, with a low of $1.86 and a high of $6.61. Its 50-day moving average stands at $5.47, while the 200-day moving average is at $4.45.

KORU Medical Systems specializes in developing and manufacturing medical devices and supplies both in the United States and internationally. The company’s product offerings include the FREEDOM60 syringe infusion system and the FreedomEdge syringe driver, which deliver essential therapies for patients with chronic illnesses such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.

As the market continues to evolve, KORU Medical Systems remains a focal point for investors seeking opportunities in the medical device sector.